Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Galmarini

Showing results (81-90 of 129) with videos related to

Pageof 13
Sort By:
Scientific Reports|January 20, 2018
Dynamic cellular maps of molecular species: Application to drug-target interactionsCarolina García, Alejandro Losada, Miguel A Sacristán, et al.
European Journal of Pharmacology|June 11, 2011
ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatmentTímea Váradi, Janos Roszik, Duarte Lisboa, et al.
Chemistry & Biology|August 27, 2011
XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloidsSascha Feuerhahn, Christophe Giraudon, Marta Martínez-Díez, et al.
Journal of Medicinal Chemistry|September 12, 2009
Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studiesAurélien Putey, Florence Popowycz, Quoc-Tuan Do, et al.
British Journal of Pharmacology|August 14, 2013
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathwaySandra Martínez, Laura Pérez, Carlos M Galmarini, et al.
Oncogene|January 20, 2004
Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemiaSanghoon Lee, François Roy, Carlos M Galmarini, et al.
Biochemical Pharmacology|November 12, 2003
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabineRomina Gamberale, Carlos M Galmarini, Paula Fernández-Calotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrugLars Petter Jordheim, Emeline Cros, Marie-Hélène Gouy, et al.
Marine Drugs|May 24, 2013
c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activityMaría J Muñoz-Alonso, Enrique Álvarez, María José Guillén-Navarro, et al.
Journal of Acquired Immune Deficiency Syndromes|May 1, 1993
An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV diseaseT S Dyner, W Lang, J Geaga, et al.
Pageof 13

Showing results (81-90 of 129) with videos related to

Sort By:
Pageof 13
Scientific Reports|January 20, 2018
Dynamic cellular maps of molecular species: Application to drug-target interactionsCarolina García, Alejandro Losada, Miguel A Sacristán, et al.
European Journal of Pharmacology|June 11, 2011
ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatmentTímea Váradi, Janos Roszik, Duarte Lisboa, et al.
Chemistry & Biology|August 27, 2011
XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloidsSascha Feuerhahn, Christophe Giraudon, Marta Martínez-Díez, et al.
Journal of Medicinal Chemistry|September 12, 2009
Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studiesAurélien Putey, Florence Popowycz, Quoc-Tuan Do, et al.
British Journal of Pharmacology|August 14, 2013
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathwaySandra Martínez, Laura Pérez, Carlos M Galmarini, et al.
Oncogene|January 20, 2004
Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemiaSanghoon Lee, François Roy, Carlos M Galmarini, et al.
Biochemical Pharmacology|November 12, 2003
In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabineRomina Gamberale, Carlos M Galmarini, Paula Fernández-Calotti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrugLars Petter Jordheim, Emeline Cros, Marie-Hélène Gouy, et al.
Marine Drugs|May 24, 2013
c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activityMaría J Muñoz-Alonso, Enrique Álvarez, María José Guillén-Navarro, et al.
Journal of Acquired Immune Deficiency Syndromes|May 1, 1993
An open-label dose-escalation trial of oral dehydroepiandrosterone tolerance and pharmacokinetics in patients with HIV diseaseT S Dyner, W Lang, J Geaga, et al.
Pageof 13